Shares of Compugen Ltd. (NASDAQ:CGEN - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.82 and traded as high as $2.25. Compugen shares last traded at $2.22, with a volume of 407,537 shares traded.
Analyst Upgrades and Downgrades
Separately, Oppenheimer started coverage on Compugen in a research report on Monday, January 13th. They set an "outperform" rating and a $4.00 price target on the stock.
View Our Latest Research Report on Compugen
Compugen Trading Down 3.4 %
The firm has a 50-day simple moving average of $1.98 and a two-hundred day simple moving average of $1.82. The company has a market capitalization of $187.93 million, a price-to-earnings ratio of 105.30 and a beta of 2.65.
Institutional Investors Weigh In On Compugen
A number of institutional investors have recently modified their holdings of CGEN. Joel Isaacson & Co. LLC grew its position in shares of Compugen by 136.4% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 30,000 shares during the period. Oppenheimer & Co. Inc. grew its position in shares of Compugen by 75.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 8,350 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Compugen by 82.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company's stock valued at $497,000 after acquiring an additional 124,190 shares during the period. Atom Investors LP boosted its holdings in Compugen by 27.5% in the 3rd quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company's stock worth $275,000 after buying an additional 32,701 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Compugen in the 4th quarter worth about $103,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.
Compugen Company Profile
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
